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invasion predicts the recurrence of HCC
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Abstract
Background and objectives: In hepatocellular carcinoma (HCC) patients, microvascular invasion (MVI) is associated
with worse outcomes regardless of treatment. No single reliable preoperative factor exists to predict MVI. The aim of
the work described here was to develop a new MVI− based mRNA biomarker to differentiate between high and low
risk patients.
Methods: Using The Cancer Genome Atlas (TCGA) database, we collected data from 315 HCC patients, including
mRNA expression and complete clinical data. We generated a seven-mRNA signature to predict patient outcomes.
The mRNA signature was validated using the GSE36376 cohort. Finally, we tested the formula in our own 53 HCC
patients using qPCR for the seven mRNAs and analyzing the computed tomography (CT) features.
Results: This seven‐mRNA signature significantly correlated with length of recurrence-free survival (RFS) and overall
survival (OS) for both the training and validation groups. RFS and OS were briefer in high risk versus low risk patients.
A Kaplan–Meier analysis also indicated that survival time was significantly shortened in the high risk group versus the
low risk group. Time-dependent receiver operating characteristic analysis demonstrated good predictive performance
for the seven-mRNA signature. The mRNA signature also acts as an independent factor according to a Multivariate
analysis. Our results are consistent with the seven-mRNA formula risk score.
Conclusion: Our research showed a novel seven-mRNA biomarker based on MVI predicting RFS and OS in HCC
patients. This mRNA signature can stratify patients into subgroups based on their risk of recurrence to help guide
individualized treatment and precision management in HCC.
Keywords: Signature hepatocellular carcinoma, mRNA, Microvascular invasion
Background
Liver cancer, a highly aggressive form of cancer, is a leading cause of cancer-related deaths worldwide, including China [1]. Hepatocellular carcinoma (HCC) makes
up 90% of liver cancer cases. Although developments in
medical oncology and surgery have revolutionized the
treatment of HCC, the prognosis remains poor, with
high recurrence. Recurrence occurs in a quarter of HCC
patients after liver transplantation and in more than
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two-thirds of patients after hepatic resection within 5
years post-remission [2]. Currently, no approved treatment reduces the risk of recurrence, progression, or
death. Thus, methods that can predict patient prognosis are urgently needed, so that effective therapeutic and
management strategies can be designed for distinct subsets of HCC patients.
The high recurrence of HCC is partly due to microvascular invasion (MVI). MVI is characterized by tumor
emboli in vessels, including veins, capillaries, and lymphatic spaces. Tumor cell dissemination is associated
with poor outcomes. All the evidence and diagnosis of
MVI is post-surgery, based on the histopathology of the
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specimen. Thus, prior to surgery, very little is known
about the diagnosis.
The prognostic scoring systems currently available
to predict survival in HCC patients before resection or
transplantation involve variables such as the tumor size
and number, serum alpha-fetoprotein (AFP), and underlying liver disease [3–6]. These scoring systems make
use of clinical information or international criterion,
while ignoring the underlying conditions and internal changes. Patients who develop HCC usually have
inflammation associated with fibrotic and cirrhotic livers, which is often accompanied by widespread lymphocyte infiltration in patients with chronic hepatitis. Thus,
the surrounding tissue microenvironment likely has an
important influence on HCC metastatic tendency. These
scoring systems may help us understand MVI but the
prognostic value of these systems is limited. Other systems incorporate morphology features to the advanced
examinations, which is an improvement [7]. These systems also make use of qualified image analysis or Radionics to determine which patients have a higher risk for
recurrence. With the advancement of microarray and
high-throughput technology, several studies have shown
a significant relationship between gene expression profiles and signatures with survival and outcome of cancer
patients, including HCC [8, 9]. Several research groups
have focused on relating gene expression to imaging.
The results of these studies offer more clues for predicting MVI, but are not very clinically applicable. Therefore,
more research is needed to improve and highlight the
function of biomarkers.
The aim of this study was to establish the differential
mRNA expression in MVI + HCC patients compared to
MVI− patients. This differential mRNA expression pattern can help physicians make more accurate diagnoses.
Better diagnoses can lead to optimization of medical
resources, such as limited organ supplies for transplantation, and improved treatment for the individual.

Materials and methods
Patients

After approval of the study by the Institutional Ethical
Committee of the First Affiliated Hospital of Zhengzhou
University, China, 53 patients were enrolled and written informed consent was obtained for all patients. Liver
cancer samples were collected from untreated patients
between September 2017 and April 2018. A three-phase
contrast-enhanced computed tomography examination
was conducted in all patients. Under double-blind conditions, two hepatobiliary radiologists with more than 10
years’ experience reviewed and analyzed the CT image
features independently. Discrepancies about image features were resolved by consensus review.
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Data research

Level 3 data from The Cancer Genome Atlas (TCGA) for
315 patients with HCC were procured from the Cancer
Genomics Browser from University of California Santa
Cruz, including mRNA expression profiles and clinical
information associated with these samples. Patients who
satisfied the following criteria were used for the model
development: (a) histologic diagnosis of HCC; (b) available microvascular invasion information, mRNA expression data, and comprehensive clinic pathological and
follow-up information; and (c) recurrence-free survival
(RFS) between 30 and 3000 days. Publicly available data
were collected from TCGA. Thus, further authorization
by the institutional ethics committee was unnecessary.
GSE36376 was procured from Gene Expression Omnibus
(GEO) for the validation group.
Construction of a risk‑score formula

Using the TCGA training set, a univariate Cox proportional regression model comparing MVI+ and MVI−
groups differential gene expression was used to identify
potential mRNAs. The relationship of these identified
mRNAs to RFS was then analyzed. A good method for
regression analysis of high-dimensional data, the least
absolute shrinkage and selection operator (LASSO) Cox
regression algorithm, was implemented for the identification of prognostic genes. In addition, the log2 fold
change and average expression levels were utilized for
ranking potential candidates. A linear combination of
selected genes weighted by their respective coefficients
was designed to develop a patient risk score formula. Risk
score = (expr Gene1 * coif Gene1) + (expr Gene2 * coif
Gene2) + … + (expr Gene5 * coif Gene5).
Identical Ƀ-values were tested in the validation set.
Survival curves of the risk scores were generated in the
training and validation sets with a Kaplan–Meier survival analysis and a two-tailed log-rank test. Prognostic
performance was determined using y calculated from the
area under the curve (AUC) from the time-dependent
receiver operating characteristic (ROC) analysis. Risk
score accuracy for predicting RFS at 1, 3, and 5 years was
determined. The independence of the predictive mRNA
signature was determined using a multivariable Cox proportional hazards regression analysis, where the dependent variable was RFS and the mRNA signature and other
clinical factors were covariables.
Statistical analysis

R language (Version 3.3.3) was utilized for all statistical analyses. The ‘survminer’, ‘survival’, and ‘survival
ROC’ packages were utilized for the creation of survival
curves and ROC curves. Differences in clinic pathological
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features were assessed with the Student’s t test or Chi
squared test. Statistical tests were two-tailed. P less than
0.05 was considered significant.

Results
Determining the prognostic mRNA signature
in the discovery group

The model was constructed from the TCGA data of 315
HCC patients. Of the 315 patients, 209 were MVI− and
106 MVI+. The mRNA expression data were compared.
The logFC value was > 0.5, P < 0.01. A total of 341 different genes were differentially expressed (Fig. 1a). A univariable Cox proportional hazards regression analysis of
the mRNA profiling data from the discovery group was
conducted resulting in 59 mRNAs with P-values less
than 0.05. A LASSO Cox regression model was utilized
to identify the most prognostic genes. We obtained two
constitute one is one standard error (SE) of the minimum
criteria and minimum criteria [10]. Based on the simplified criteria, the lse model was used (Fig. 1b, c), resulting
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in 12 candidate genes. Genes were further filtered with
a stepwise regression using a multivariable Cox proportional hazards regression model. Seven genes (IM2A,
STAG3, ADH1C, NEIL3, GULP1, PPAP2C, CKMT1B)
were identified. Correlations among the seven genes in
the TCGA cohorts were evaluated using a heatmap. The
risk score was calculated using the expression levels of
the seven genes and the corresponding Coif. The resulting risk-score formula was: risk score = + (CKMT1B*−0
.15788) + (PPAP2C*−0.06074) + (GULP1*0.111848) + (N
EIL3*0.114841)) + (ADH1C *−0.10131)) + (STAG3*−0.1
9945) + (ITM2A*−0.3719).
Patients in the training cohort were categorized as high
risk or low risk based on the optimum cutoff(−4.52432).
The training cohort consisted of 87 high risk patients
with 54 recurrences and 184 low risk patients with 53
recurrences. High risk patients had worse outcomes
compared to low risk patients (P < 0.0001; Fig. 2a), as
determined by the Kaplan–Meier analysis. Notably, if
the mRNA expression value was weighted by a negative

Fig. 1 The different mRNA expression between MVI+ and MVI− in TCGA discovery group. a Univariate Cox regression analysis shows 341 genes
significantly related to RFS. b A tenfold cross-validation for tuning parameter selection in the LASSO model. c The LASSO coefficient profiles for the
associated genes
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Fig. 2 Kaplan–Meier analysis of RFS of the formula in different groups. a Risk formula analysis in the TCGA set: The recurrence time in high and low
risk groups were applied using the Kaplan–Meier analysis. b The distribution of the risk formula, patients’ status, and the expression heat map for the
discovery set. c Risk formula analysis in the GEO set: Recurrence time in high and low risk groups based on the Kaplan–Meier analysis. d Distribution
of the risk formula, patients’ status, and the expression heat map for the discovery set. e Risk formula analysis in the 53 patient set: Recurrence time
in high and low risk groups based on the Kaplan–Meier analysis. f The distribution of the risk formula, patients’ status, and the expression heat map
for the discovery set

coefficient in this formula, the gene was protective with
low risk for recurrence; a positive coefficient signified
that the gene was harmful to the prognosis. In the discovery group, patients with low risk scores had a longer RFS
time (median 572 days) compared to high risk patients
(median 239 days). According to the heat map, the protective five mRNAs were increased in the low risk group,
while the other two genes (NEIL3, GULP1) were downregulated (Fig. 2b). Thus, the risk-score formula stratified
the HCC patients based on the RFS.
The prognostic performance of the seven mRNA signature was assessed with a time-dependent ROC curve
analysis. AUC values for the RNA signature were 0.782,
0.793, and 0.749 for predicting recurrence in the TCGA
set at 1, 3, and 5 years (Additional file 1: Figure S1). AUC
values exceeded 0.7 [11], indicating that our selection

mRNA formula was suitable for predicting recurrence in
HCC patients.
Prognostic value of the seven mRNA formula
in the validation groups

To validate the seven mRNA risk score formula, we used
GSE36376 containing 401 patients. Similar to the discovery group, high risk patients had shorter recurrence times
and worse outcomes than low risk patients (P = 0.00024).
There were 97 high risk patients with 61 recurrences,
whereas there were 304 low risk patients with 184 recurrences. The RFS time in low risk patients was longer
compared to high risk patients (Fig. 2c, d). In addition,
the five protective mRNAs increased in low risk patients;
the opposite occurred in high risk patients. These results
are consistent with the data from the discovery group.
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Thus, these seven mRNAs are risk factors for recurrence
in HCC patients, supporting the risk prediction model.
The relationship between risk scores and clinical
pathological factors

We conducted a set of predefined stratified analyses to
identify whether the seven mRNAs have an independent predictive ability in the discovery and validation sets
separately. A Cox multivariate regression analysis was
performed with clinical characteristics, including age,
gender, tumor stage, and WHO grade. The RFS probabilities for high and low risk groups, visualized with Kaplan–
Meier plots (Additional file 1: Figure S2 and Figure S3),
indicate that the mRNA signature is an independent factor for predicting RFS in HCC patients, both in the discovery and validated sets (Table 1).
Evaluation of the formula with our 53 patient set

Fifty-three fresh liver cancer tissues were collected from
patients (Table 2) without any treatment. Total mRNA
was isolated using TRIzol reagent (Invitrogen, Waltham,
MA). A PrimeScript RT Reagent Kit was used for reverse
transcription of the isolated RNA (Takara Bio, Otsu,
Shiga, Japan). Gene expression levels were quantified
using qRT-PCR. In the 53 HCC patients, RFS was shorter
in the 19 high risk patients versus the 34 low risk patients.
In the high risk group, 18 patients had recurrences,

while 15 low risk patients had recurrences. The low
risk patients had longer RFS than high risk patients
(617.5 days VS 413 days). In this patient group, the seven
mRNA formula differentiated the high risk from low risk
HCC patients, with respect to RFS (Fig. 2e, f ).
Imaging examination is widely used for assessing
tumors. Therefore, for our patient group, we evaluated
the association between imaging features and the mRNA
signature. In previous research, we found that tumor
dimension, non-smooth tumor margins, peritumoral
enhancement, and TTPVI have the best ability to predict
MVI in HCC [12]. Non-smooth tumor margins, peritumoral enhancement, and TTPVI are related to tumor
size [13]. Therefore, we did not collect information about
tumor size. After comparing the CT images, we found
more “worrisome” features in high risk patients versus
low risk patients (Fig. 3). Patients had high similarities
between the imaging features and the mRNA formula
(Fig. 4). In other words, the mRNA formula was consistent with our radiology consensus.
Cancer-related death is the most important index for
patients. Thus, we assessed the association of risk score
with overall survival (OS) time. Data from the discovery
group indicated that patients with low risk scores had
longer OS times than patients with high risk scores. Mortality rate in high risk patients was significantly elevated
compared to low risk patients (Fig. 5), indicating that

Table 1 Multivariable Cox regression analysis of RFS in HCC patients in the discovery, validation and our patient set
Charcateristic

Multivariable analysis
Coef

Discovery set (n = 271)

HR

Lower 95

Upper 95

z

P value

Risk sore

1.0001

2.7186

2.1975

3.3633

9.2118

3.21E−20

Age_ ≥ 65/, < 65

0.2566

1.2925

0.8791

1.9005

1.3048

0.1919

Gender

Neoplasm-histologic-grade
Pathologic_M

− 0.0778

− 0.1161

0.9251

0.6121

1.398

0.8903

0.6956

1.1394

− 0.3694

0.7118

− 0.9228

0.3561

0.066

1.0683

0.863

1.3224

0.6071

0.5437

Pathologic_N

0.1106

1.117

0.911

1.3695

1.0639

0.2873

Pathologic_T

0.0183

1.0185

0.8327

1.2457

0.1785

0.8583

Pathologic_stage

0.0231

1.0234

0.8378

1.2501

0.2268

0.8205

Validation set (n = 401)
Riskscore

Age
Gender
AJCC_T_stage
Our sets (n = 53)
Risk.socre

TNM.stag1ng
Gender
Age

0.96

2.6117

1.5394

4.4308

3.5597

0.0004

− 0.1479

0.8625

0.6456

1.1523

− 1.0007

0.317

− 0.1514

0.69193

0.8595

0.6312

1.1703

1.9976

1.7208

2.3189

− 0.9615
9.0928

0.3363
9.66E−20

1.4865

4.4217

2.0409

9.5799

3.7685

0.0002

− 0.1199

0.887

0.5506

1.429

0.6221

0.6561

1.9273

0.6694

5.5486

− 0.4929
1.2161

0.2239

0.0031

1.0031

0.407

2.4722

0.0067

0.9946
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Table 2 Clinical characteristics of patients in the 53
patients set
Demographics
Gender
Male

45

Female

8

Age
Median (range)

50 (28–77)

Risk factors
HBV+

30

HCV+

8

Alcohol

6

Others

9

TNM stage
I

15

II

22

IIIA

10

IIIB

5

IIIC

1

MVI+

28

MVI−

25

Tumor features
Nonsmooth tumor margin
Irregular circumferential peritumoral enhancement
TTPVI
Events

32 + 21−

23 + 30−

34 + 19−

Recurrence

33

Noreurrence

20

Deaths
Median follow up(days)

784 (63–1865)

RFS time(days)

454 (63–1597)

TTPVI = two-trait predictor of venous invasion: Internal arteries and hypodense
halos

the seven-mRNA formula might play an important role
in identifying patients with more risk of recurrence and
worse outcomes. This formula showed the same effect in
our 53 patient set. When patients were stratified according to tumor grade, the seven-mRNA formula could predict the recurrence based on the risks. In other words,
the formula has the ability to divide the HCC patients
with respect to OS and RFS based on the MVI.

Discussion
Although diagnosis and management of HCC have
advanced, the median patient survival time is less than
8 months; HCC is still a highly malignant cancer [14].
Even if patients choose curative treatment, such as surgical resection, liver transplantation, and local ablation,
the frequent recurrence impedes successful outcome. For
personalized patient management and elucidation of the
biological features of recurrence, the development of a

feasible and reliable signature that can predict high risk
of recurrence is necessary. In our study, we developed
and validated an mRNA formula which predicts recurrence. This is the first research based on mRNA to predict recurrence.
A risk score formula that can estimate HCC recurrence
and prognosis has value in guiding the management of
HCC. A risk score may help doctors identify candidates
for liver transplantation and guide the design of clinical therapies. For example, patients who have high risk
scores may not be the best candidates for liver transplantation compared to low risk patients, but may be candidates for more aggressive treatments.
Cancer gene expression can reveal the etiology, prognosis, and treatment response [15, 16]. With gene
sequencing advancements, a large number of messenger
RNAs (mRNA) have been explored in relation to cancer. Our study revealed that a seven mRNA signature
(ITM2A, STAG3, ADH1C, NEIL3, GULP1, PPAP2C,
CKMT1B) is associated with HCC recurrence. Patients
with high mRNA signature based risk scores have shorter
recurrence and OS times. The mRNAs in the predictive
seven mRNA risk score shown below were also reported
in other cancers. Risk score = + (CKMT1B*−0.15788)
+ ( P PA P 2 C * − 0 . 0 6 0 7 4 ) ) + ( G U L P 1 * 0 . 1 1 1 8 4 8 )
+(NEIL3*0.114841)) + (ADH1C *−0.10131)) + (STAG3
*−0.19945) + (ITM2A *−0.3719). CKMT1B is involved
in breast cancer. However, in contrast to our study, high
CKMT1B expression was associated with poor outcomes
[17–20]. CKMT1B encodes for a protein responsible for
transferring high energy phosphate from mitochondria
to cytosolic creatine. Thus, the upregulated expression
of CKMT1B may result in more energy for the growing tumor tissue. This gene is also a porin of the mitochondrial membrane pore and impacts apoptosis. More
research is necessary to elucidate the role of CKMT1B
in HCC. PPAP2C belongs to the phosphatidic acid phosphatase enzyme family responsible for regulating dephosphorylation of lipid phosphates [21, 22]. This gene is
overexpressed in many cancers, including ovarian carcinoma, lung cancer, and bladder, prostate cancers, as well
as sarcomas. PPAP2C can regulate cell proliferation and
may be an anticancer drug. This is consistent with our
finding that this PPAP2C plays a protective role in HCC
patients. GULP1 expression is significantly decreased
in cancer tissue versus normal tissues and highly hypermethylated. Consistent with our data, GULP1 expression is associated with outcomes in ovarian cancer
patients [23, 24]. Elevated expression of NEIL3 occurs in
many human cancer cell types and tissues and is associated with primary malignant melanomas and metastasis
[25–27]. NEIL3 may be a latent tumor suppressor gene
for hepatocellular carcinoma [28]. This is consistent
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Fig. 3 The CT features between the high and low risk group in the 53 patients set: The red column displays the high risk group, while the green
column displays the low risk group. a The nonsmooth tumor margins, b the peritumoral enhancement, and c TTPVI

Fig. 4 Computed tomography scan revealed the patients with different RFS. a peritumoral enhancement: recurrence 3.2 months, external portion
enhancing in the arterial phase (arrows). b nonsmooth tumor margin positive: recurrence 4.5 months, focal extranodular extension (arrows) in the
venous phase. c The two-trait algorithm predictive of MVI (TTPVI) positive: recurrence 2.8 months, blue arrows show internal artery and lower image
means noncontinuous hypoattenuating halos

with our risk formula. The ADH1C gene has two alleles
(ADH1C*1 and ADH1C*2), which code for the γ1 and γ2
enzyme subunits with different in vitro kinetic properties. ADH1C is associated with susceptibility to oral cancer, and may have anti-oncogenic, proapoptotic effects.
In addition, ADHIC may be involved in rapid metabolism of ethanol and accumulation of acetaldehyde in

tissue, resulting in increased cancer risk. We found that
ADH1C may be protective in HCC. HCC is often associated with alcohol consumption; thus, ADH1C may have
the same mechanism in HCC patients [29–31]. STAG3
has a tumor suppression function in ovarian cancer. This
is consistent with our finding. STAG3 is also associated
with lymphoma, and colorectal and testicular cancers
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Fig. 5 Kaplan–Meier analysis of OS of the formula in different groups and stages. a Risk formula analysis in the TCGA set: The OS time in high and
low risk groups based on the Kaplan–Meier analysis, b Kaplan–Meier curves obtained for TCGA set patient stages I and II. c Kaplan–Meier curves
obtained for TCGA set patient stages III and IV. d Risk formula analysis in the GEO set: The OS time in high and low risk groups based on the Kaplan–
Meier analysis. e Kaplan–Meier curves obtained for GEO set patient stages I and II. f Kaplan–Meier curves obtained for GEO set patient stages III and
IV. g Risk formula analysis in the 53 patient set: The OS time in high and low risk groups based on the Kaplan-Meier analysis, h Kaplan–Meier curves
obtained for 53 patient stages I and II, i Kaplan–Meier curves obtained for 53 patient stages III and IV

[32, 33]. ITM2A is GATA3-related gene and has been
reported as a downstream target in T-cell lymphoma.
ITM2A also acts as a tumor suppressor of ovarian cancer
via G2/M cell cycle arrest. According to our study, this
gene is also protective in HCC [34–36].

This seven-mRNA risk formula was validated in three
independent cohorts, including our fifty-three HCC
patient set. Because imaging examination is popular in
the clinical practice, we also compared our finding and
the accepted MVI imaging feature; the results from this
comparison are consistent concerning recurrence and
OS. All the results showed that this mRNA signature is
worthy to apply in clinical practice.
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Conclusion
This seven-mRNA risk formula is an independent factor from other clinical traits for micro-vessel invasion.
Therefore, the mRNA risk formula can be a predictor
of HCC recurrence. In summary, our finding has tremendous value in the diagnosis and treatment in HCC
patients, especially in predicting the recurrence of MVI.
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